Use of Toll-Like Receptor 4 Antagonists for the Treatment or Prevention of Osteoarthritic Conditions

• US 20090136509A1
• Filed: 10/31/2008
• Published: 05/28/2009
• Est. Priority Date: 10/31/2007
• Status: Abandoned Application

• Current Assignee: Centocor Incorporated (Johnson & Johnson)
• Original Assignee: Centocor Incorporated (Johnson & Johnson)
• Inventors: Wu, Linda, Ware, Mark, Stojanovic-Susulic, Vedrana, Blake, Simon
• Application Number:
  US12/262,699
• Publication Number:
  US 20090136509A1
• Time in Patent Office: Days
• US Class Current: 424/139.100
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: C07K 16/2896 against molecules with a "CD"-designation, not provided for elsewhere
• CPC Class Codes: C07K 2317/32 specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
• CPC Class Codes: C07K 2317/76 Antagonist effect on antigen, e.g. neutralization or inhibition of binding
• CPC Class Codes: C07K 2319/30 Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
• CPC Class Codes: C07K 2319/32 fusions with soluble part of a cell surface receptor, "decoy receptors"

Abstract

Methods for treating or preventing osteoarthric conditions using Toll-Like Receptor 4 (TLR4) antagonists are disclosed.

Claims

1. A method of treating an osteoarthritic condition comprising administering a therapeutically effective amount of a Toll Like Receptor 4 (TLR4) antagonist to a patient in need thereof for a time sufficient to treat the osteoarthritic condition.

2. The method of claim 1 wherein the TLR4 antagonist is an isolated antibody reactive with TLR4.

3. The method of claim 1 wherein the TLR4 antagonist is an isolated antibody reactive with TLR4 and having the antigen binding ability of the monoclonal antibody MTS510.

4. The method of claim 1 wherein the TLR4 antagonist comprises the extracellular domain of a TLR4.

5. The method of claim 4 wherein the TLR4 antagonist is a peptide chain comprising the amino acid sequence shown in SEQ ID NO:

4.

6. The method of claim 4 wherein the TLR4 antagonist is a peptide chain comprising the amino acid sequence shown in SEQ ID NO:

10.

7. A method of preventing an osteoarthritic condition comprising administering a therapeutically effective amount of a TLR4 antagonist to a patient in need thereof for a time sufficient to prevent the osteoarthritic condition.

8. The method of claim 7 wherein the TLR4 antagonist is an isolated antibody reactive with TLR4.

9. The method of claim 7 wherein the TLR4 antagonist is an isolated antibody reactive with TLR4 and having the antigen binding ability of the monoclonal antibody MTS510.

10. The method of claim 7 wherein the TLR4 antagonist comprises the extracellular domain of a TLR4.

11. The method of claim 10 wherein the TLR4 antagonist is a peptide chain comprising the amino acid sequence shown in SEQ ID NO:

4.

12. The method of claim 10 wherein the TLR4 antagonist is a peptide chain comprising the amino acid sequence shown in SEQ ID NO:

10.